Work

Figure S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease

Year: 2023

Type: other

Abstract: Figure S1 - PDF file 23K, Mean serum siltuximab concentration following the first dose of 12 mg/kg by disease type in patients evaluable for pharmacokinetics analysis in cohorts 3, 5, and 6. Abbreviations: CD, Castleman's disease; Inf, infusion; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma

DOI: 10.1158/1078-0432.22454315.v1

Authors: Razelle Kurzrock, Peter M. Voorhees, Corey Casper, Richard R. Furman, Luis Fayad, Sagar Lonial, Hossein Borghaei, Sundar Jagannath, Lubomir Sokol, Saad Z. Usmani, Helgi van de Velde, Xiang Qin, Thomas A. Puchalski, Brett Hall, Manjula Reddy, Ming Qi, Frits van Rhee

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361909254

Cites:

Cited by:

Related to: 10